Source: Virtual Congress 2020 – Biological mechanisms of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Fu (Suzhou, China), Y. Zhang (Suzhou, China), Z. Liu (Suzhou, China), J. Huang (Suzhou, China). The upregulation of Osteopontin mediates acquired resistance to EGFR-TKI in NSCLC through Integrin/FAK signaling. 1762

Member's Comments

No comment yet.

Related content which might interest you: Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020 TRAP1 downregulation could overcome gefitinib resistance in NSCLC via EMT reversal Source: International Congress 2018 – Lung cancer: novel molecular markers and mechanisms Year: 2018 Salinomycin suppresses TGF-ß1-induced EMT by down-regulating MMP-2,9 via AMPK-SIRT1 pathway in a non-small cell lung cancer Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017 Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker? Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 CDCA promotes non-small-cell lung cancer (NSCLC) migration by regulating Akt/Erk1/2 signaling pathways Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology Year: 2019 Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 KPNB1-mediated PD-L1 nuclear translocation promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signalling pathway Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020 Blocking beta adrenergic signaling may be a target for overcoming EGFR TKI resistance. Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 The effect of adhesion molecule CEACAM1 and chemokine receptor CXCR4 expression on prognosis of non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005 The selection of candidate microRNA biomarkers of acquired drug resistance in the lung adenocarcinoma cells treated with EGFR TKI Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD Year: 2019 Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019 Toll-like receptor 3 is up-regulated and enhances anti-proliferative function in human non-small cell lung cancer Source: Annual Congress 2008 - Lung cancer and other malignant diseases involving the lungs Year: 2008 Caspase recruitment domain containing protein 9 suppresses non-small cell lung cancer proliferation and invasion via inhibiting MAPK/p38 pathway Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 EVI5 is an oncogene that regulates the proliferation and metastasis of NSCLC cells Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 Does acute phase protein alpha1-antitrypsin modulate apoptosis-autophagy crosstalk resulting in resistance of NSCLC cells to cancer drugs? Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021 Enhanced FGFR signaling correlates with erlotinib/bevacizumab response in advanced non-squamous non-small cell lung cancer Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 NTHi-promoted proliferation of K-ras-induced early lung cancer lesions is fully dependent on Toll-like receptor signaling Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017 Endotoxin induces proliferation of NSCLC cells by a COX-2 dependent manner – Role of CD14, TLRs and EGFR signaling Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010 Activation of CD40-CD40L signal could enhance the sensitivity of chemotherapy to lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 704s Year: 2004